Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
5.37
-0.08 (-1.47%)
Apr 29, 2026, 11:15 AM EDT - Market open
Quoin Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 3.82 | 3.62 | 2.4 | 2.86 | 7.48 | Upgrade
|
| Short-Term Investments | 14.93 | 10.43 | 8.29 | 9.99 | - | Upgrade
|
| Cash & Short-Term Investments | 18.75 | 14.06 | 10.69 | 12.85 | 7.48 | Upgrade
|
| Cash Growth | 33.35% | 31.44% | -16.79% | 71.78% | 2210.70% | Upgrade
|
| Prepaid Expenses | 1.26 | 0.87 | 0.59 | 0.52 | 0.72 | Upgrade
|
| Total Current Assets | 20.01 | 14.93 | 11.29 | 13.37 | 8.2 | Upgrade
|
| Other Intangible Assets | 0.38 | 0.48 | 0.58 | 0.7 | 0.81 | Upgrade
|
| Other Long-Term Assets | - | 0.3 | 0.3 | 0.38 | 0.35 | Upgrade
|
| Total Assets | 20.39 | 15.71 | 12.17 | 14.46 | 9.36 | Upgrade
|
| Accounts Payable | 1.26 | 0.91 | 0.53 | 0.61 | 0.92 | Upgrade
|
| Accrued Expenses | 3.68 | 2.68 | 2.45 | 2.32 | 2.43 | Upgrade
|
| Current Portion of Long-Term Debt | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | Upgrade
|
| Other Current Liabilities | - | - | - | - | 0.62 | Upgrade
|
| Total Current Liabilities | 5.55 | 4.18 | 3.58 | 3.53 | 4.58 | Upgrade
|
| Long-Term Debt | 1.72 | 2.32 | 2.92 | 3.52 | 4.12 | Upgrade
|
| Total Liabilities | 7.27 | 6.5 | 6.51 | 7.05 | 8.7 | Upgrade
|
| Additional Paid-In Capital | 84.09 | 64.37 | 51.87 | 47.86 | 31.66 | Upgrade
|
| Retained Earnings | -70.97 | -55.17 | -46.2 | -37.52 | -28.07 | Upgrade
|
| Treasury Stock | - | - | - | -2.93 | -2.93 | Upgrade
|
| Comprehensive Income & Other | -0 | - | - | - | - | Upgrade
|
| Shareholders' Equity | 13.12 | 9.2 | 5.66 | 7.41 | 0.66 | Upgrade
|
| Total Liabilities & Equity | 20.39 | 15.71 | 12.17 | 14.46 | 9.36 | Upgrade
|
| Total Debt | 2.32 | 2.92 | 3.52 | 4.12 | 4.72 | Upgrade
|
| Net Cash (Debt) | 16.42 | 11.13 | 7.17 | 8.73 | 2.76 | Upgrade
|
| Net Cash Growth | 47.50% | 55.25% | -17.85% | 216.41% | - | Upgrade
|
| Net Cash Per Share | 15.37 | 84.50 | 278.59 | - | - | Upgrade
|
| Filing Date Shares Outstanding | 1.8 | 0.59 | 0.11 | 0.03 | - | Upgrade
|
| Total Common Shares Outstanding | 1.5 | 0.26 | 0.03 | 0.01 | - | Upgrade
|
| Working Capital | 14.46 | 10.75 | 7.7 | 9.84 | 3.62 | Upgrade
|
| Book Value Per Share | 8.76 | 36.00 | 200.81 | 641.72 | - | Upgrade
|
| Tangible Book Value | 12.74 | 8.72 | 5.08 | 6.7 | -0.15 | Upgrade
|
| Tangible Book Value Per Share | 8.50 | 34.11 | 180.13 | 580.68 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.